JGC
SLNO

J. Goldman & Co’s Soleno Therapeutics SLNO Stock Holding History

J. Goldman & Co’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,658
Closed -$1.33M – 718
2025
Q3 		$1.33M Sell
19,658
-22,926
-54% -$1.7M 0.03% 307
2025
Q2 		$3.57M Buy
42,584
+14,111
+50% +$1.06M 0.09% 230
2025
Q1 		$2.03M Sell
28,473
-16,869
-37% -$821K 0.05% 292
2024
Q4 		$2.04M Buy
45,342
+23,570
+108% +$1.22M 0.05% 276
2024
Q3 		$1.1M Sell
21,772
-5,166
-19% -$247K 0.03% 284
2024
Q2 		$1.1M Buy
+26,938
New +$1.14M 0.03% 292
2024
Q1 		– Sell
-73,252
Closed -$2.95M – 514
2023
Q4 		$2.95M Buy
73,252
+7,252
+11% +$206K 0.12% 162
2023
Q3 		$1.95M Sell
66,000
-54,799
-45% -$332K 0.07% 204
2023
Q2 		$518K Sell
120,799
-148,644
-55% -$639K 0.02% 290
2023
Q1 		$577K Buy
269,443
+156,944
+140% +$353K 0.02% 256
2022
Q4 		$223K Buy
112,499
+67,500
+150% +$83.9K 0.01% 307
2022
Q3 		$75K Buy
+44,999
New +$110K ﹤0.01% 347
2021
Q1 		– Sell
-7,992
Closed -$231K – 517
2020
Q4 		$231K Sell
7,992
-8,140
-50% -$235K 0.01% 324
2020
Q3 		$607K Sell
16,132
-10,360
-39% -$303K 0.04% 241
2020
Q2 		$882K Buy
26,492
+17,083
+182% +$740K 0.05% 199
2020
Q1 		$336K Sell
9,409
-4,479
-32% -$191K 0.04% 195
2019
Q4 		$612K Buy
+13,888
New +$355K 0.04% 209

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

J. Goldman & Co's SLNO Position: Q4 2025 in Review

J. Goldman & Co sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 19,658 shares — an estimated $1.33M sold.

J. Goldman & Co first reported a position in SLNO in Q4 2019 and held it in 17 quarters. The position peaked at $3.57M in Q2 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • J. Goldman & Co reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 19,658 Soleno Therapeutics shares in Q4 2025, an estimated $1.33M.
  • J. Goldman & Co first reported a position in Soleno Therapeutics in Q4 2019 and held it in 17 quarters.
  • J. Goldman & Co's Soleno Therapeutics position peaked at $3.57M in Q2 2025.
  • 248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.